View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Gastroenterology 2023;165:1588 doi 10.1053/j.gastro.2022.01.047
Guselkumab induced greater clinical and endoscopic improvements in patients with Crohn’s disease versus placebo, with a favourable safety profile in this Phase 2 trial by Sandborn, et al.
Lancet 2022;399:2031–36 doi: 10.1016/S0140-6736(22)00466-4
Maintenance treatment with risankizumab was associated with an improvement in coprimary endpoints of clinical remission and endoscopic response in patients with Crohn’s disease compared with placebo.
Lancet 2022;399:2015–30 doi 10.1016/S0140-6736(22)00467-6
Risankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active Crohn’s disease, though there were no significant differences in efficacy between 600mg and 1200mg doses.
N Engl J Med 2021;385:1280–91 doi: 10.1056/NEJMoa2033617
Patients receiving ozanimod displayed a significant improvement in clinical response and all secondary endpoints during both the 10-week induction and 52-week maintenance study periods. Percentage of patients achieving clinical remission at Weeks 10 and 52 was the primary endpoint.
The Lancet 2021;397:2372–2384 doi: 10.1016/S0140-6736(21)00666-8
Treatment of patients with UC with filgotinib 200 mg was associated with an increase in clinical remission at Week 10 and Week 58. The proportion of patients with clinical remission at Week 58 was significantly greater in patients who continued FIL 200 mg therapy throughout the trial. The incidence of TEAEs was similar across all treatment groups.
J Am Acad Dermatol 2024;90:82–90 doi: 10.1016/j.jaad.2023.08.097
The majority of patients receiving persistent risankizumab therapy achieved clear or clear/almost clear skin at 12 months and patients reported significant reductions in DLQI scores, PROs (fatigue, skin pain, overall itch), and work and activity impairment.
Modern Rheumatology. 2024;34(3):584–91 doi: 10.1093/mr/road061
This study by Karakas, et al. found that obesity did not affect secukinumab treatment response and drug retention in ankylosing spondylitis patients.
J Clin Rheumatol 2024 doi 10.1097/RHU.0000000000002069
This study by Goswami, et al. found that tofacitinib showed comparable effectiveness with adalimumab in axSpA patients at the sixth month.
Rheumatol Ther 2024 doi: 10.1007/s40744-024-00656-3
This post-hoc analysis by Baraliakos, et al. found a response in short-term index studies was maintained in the long-term OLE studies, and where no response occurred in the index studies, continued treatment led to a response in a large proportion of patients.
Rheumatol Ther 2024 doi: 10.1007/s40744-024-00654-5 Epub ahead of print
Risankizumab therapy was associated with significant and sustained improvement in multiple disease domains from Week 52 through Week 100, compared with placebo. Kristensen et al. investigated the safety, efficacy and tolerability of 100-week risankizumab therapy in PsA patients with previous inadequate response to ≥1 csDMARD, using data from KEEPsAKE 1 trial.
